Compare Stocks: PULM, UPC, COCP, and LPCN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCP Cocrystal Pharma	$1.11 -3.1%	$1.11	$0.76 ▼ $2.03	$21.38M	1.48	844,968 shs	41,079 shs
LPCN Lipocine	$2.07 +1.0%	$2.17	$1.81 ▼ $12.37	$17.06M	0.4	185,242 shs	19,764 shs
PULM Pulmatrix	$1.48 -5.7%	$1.55	$1.16 ▼ $5.50	$5.40M	1.93	41,129 shs	24,143 shs
UPC Universe Pharmaceuticals	$4.34 -3.6%	$4.87	$2.00 ▼ $17.96	$21.79M	1.68	736,488 shs	7,842 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCP Cocrystal Pharma	0.00%	-2.14%	+1.33%	+10.10%	-5.37%
LPCN Lipocine	0.00%	-2.38%	-16.33%	-17.00%	-38.81%
PULM Pulmatrix	0.00%	-2.48%	+12.95%	-9.25%	-67.76%
UPC Universe Pharmaceuticals	0.00%	-5.26%	+11.66%	-25.00%	-4.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCP Cocrystal Pharma	$1.11 -3.1%	$1.11	$0.76 ▼ $2.03	$21.38M	1.48	844,968 shs	41,079 shs
LPCN Lipocine	$2.07 +1.0%	$2.17	$1.81 ▼ $12.37	$17.06M	0.4	185,242 shs	19,764 shs
PULM Pulmatrix	$1.48 -5.7%	$1.55	$1.16 ▼ $5.50	$5.40M	1.93	41,129 shs	24,143 shs
UPC Universe Pharmaceuticals	$4.34 -3.6%	$4.87	$2.00 ▼ $17.96	$21.79M	1.68	736,488 shs	7,842 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCP Cocrystal Pharma	0.00%	-2.14%	+1.33%	+10.10%	-5.37%
LPCN Lipocine	0.00%	-2.38%	-16.33%	-17.00%	-38.81%
PULM Pulmatrix	0.00%	-2.48%	+12.95%	-9.25%	-67.76%
UPC Universe Pharmaceuticals	0.00%	-5.26%	+11.66%	-25.00%	-4.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
LPCN Lipocine	2.00	Hold	$4.00	93.24% Upside
PULM Pulmatrix	1.00	Sell	N/A	N/A
UPC Universe Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PULM, UPC, COCP, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	LPCN Lipocine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.46 per share	N/A
LPCN Lipocine	$1.98M	8.61	N/A	N/A	$2.61 per share	0.79
PULM Pulmatrix	$7.81M	0.69	N/A	N/A	$2.45 per share	0.60
UPC Universe Pharmaceuticals	$17.86M	1.22	N/A	N/A	$99.64 per share	0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
PULM Pulmatrix	-$5.16M	-$1.10	N/A	N/A	N/A	N/A	-125.65%	-95.19%	11/5/2026 (Estimated)
UPC Universe Pharmaceuticals	-$3.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest PULM, UPC, COCP, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/13/2026	Q2 2026	PULM Pulmatrix	-$2.00	-$0.29	+$1.71	-$0.29	N/A	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million
7/29/2026	Q2 2026	UPC Universe Pharmaceuticals	N/A	-$1.38	N/A	-$1.38	N/A	$4.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COCP Cocrystal Pharma	N/A	1.24	1.24
LPCN Lipocine	N/A	11.48	11.48
PULM Pulmatrix	N/A	4.70	4.70
UPC Universe Pharmaceuticals	0.04	4.05	3.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COCP Cocrystal Pharma	6.72%
LPCN Lipocine	9.11%
PULM Pulmatrix	11.84%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
COCP Cocrystal Pharma	39.40%
LPCN Lipocine	4.69%
PULM Pulmatrix	0.62%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
LPCN Lipocine	14	8.24 million	7.86 million	No Data
PULM Pulmatrix	2	3.65 million	3.63 million	Not Optionable
UPC Universe Pharmaceuticals	216	5.02 million	2.14 million	N/A

PULM, UPC, COCP, and LPCN Headlines

Recent News About These Companies

Universe Pharmaceuticals INC (NASDAQ:UPC) Stock Short Interest Rises 154.7%

September 28, 2026 | americanbankingnews.com

Universe Pharmaceuticals shares rise 22.6% premarket with no new catalyst identified

September 2, 2026 | msn.com

Universe Pharmaceuticals (UPC) stock soars over 38% after-hours: Here's what's going on

September 2, 2026 | msn.com

Universe Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:UPC

July 18, 2026 | benzinga.com

Universe Pharmaceuticals INC - Ordinary Shares - Class A

July 17, 2026 | money.usnews.com

Universe Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:UPC | Benzinga

June 29, 2026 | benzinga.com

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

June 29, 2026 | markets.businessinsider.com

China's Universe Pharmaceuticals (NASDAQ: UPC) Makes Nasdaq Top Gainer List on Acquisition News

June 29, 2026 | investorideas.comI

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 27, 2026 | finanznachrichten.de

Universe Pharmaceuticals Inc

June 26, 2026 | fool.com

UPC stock surges 288% after hours — what’s driving the rally?

June 26, 2026 | msn.com

Universe Pharmaceuticals to acquire Best Praise for $10.75M

June 26, 2026 | seekingalpha.com

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 26, 2026 | globenewswire.com

Universe Pharmaceuticals Stock News

June 17, 2026 | benzinga.com

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

June 16, 2026 | businesswire.com

Universe Pharmaceuticals Incorporation Class A

April 29, 2026 | edition.cnn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% â€“ Time to Sell?

April 25, 2026 | defenseworld.netD

Universe Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share Structure

February 11, 2026 | tipranks.com

Universe Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026

February 11, 2026 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

February 11, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PULM, UPC, COCP, and LPCN Company Descriptions

Cocrystal Pharma NASDAQ:COCP

$1.11 -0.04 (-3.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.14 +0.02 (+2.25%)

As of 05:29 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Lipocine NASDAQ:LPCN

$2.07 +0.02 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 +0.02 (+0.72%)

As of 04:10 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Pulmatrix NASDAQ:PULM

$1.48 -0.09 (-5.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.48 0.00 (0.00%)

As of 04:10 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Universe Pharmaceuticals NASDAQ:UPC

$4.34 -0.16 (-3.56%)

Closing price 04:00 PM Eastern

Extended Trading

$4.06 -0.28 (-6.52%)

As of 04:53 PM Eastern

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PULM, UPC, COCP, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PULM, UPC, COCP, and LPCN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PULM, UPC, COCP, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PULM, UPC, COCP, and LPCN Company Descriptions

Cocrystal Pharma NASDAQ:COCP

Lipocine NASDAQ:LPCN

Pulmatrix NASDAQ:PULM

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PULM, UPC, COCP, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PULM, UPC, COCP, and LPCN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PULM, UPC, COCP, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PULM, UPC, COCP, and LPCN Company Descriptions

Cocrystal Pharma NASDAQ:COCP

Lipocine NASDAQ:LPCN

Pulmatrix NASDAQ:PULM

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools